

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 ALASKA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. *ANNUAL* MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. *ANNUAL* MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	117,291	681	7,744	27,233	81,495	138	1,005,986	6,713	80,666	191,243	726,598	766
Age												
5 and younger	31,207	0	403	0	30,804	0	266,147	0	3,671	0	262,476	0
6-14	37,466	0	825	7	36,634	0	351,124	0	8,964	48	342,112	0
15-20	19,432	0	677	4,894	13,854	7	162,747	0	7,174	34,382	121,164	27
21-44	22,274	1	2,395	19,589	203	86	160,878	9	25,174	134,482	846	367
45-64	6,139	11	3,343	2,740	0	45	57,354	115	34,550	22,317	0	372
65-74	471	369	100	2	0	0	4,754	3,612	1,130	12	0	0
75-84	243	242	1	0	0	0	2,513	2,510	3	0	0	0
85 and older	58	58	0	0	0	0	467	467	0	0	0	0
Unknown	1	0	0	1	0	0		0	0	2	0	0
Gender												
Female	64,621	445	3,945	20,277	39,816	138	542,531	4,496	41,660	140,260	355,349	766
Male	52,666	236	3,799	6,956	41,675	0	463,428	2,217	39,006	50,983	371,222	0
Unknown	4	0	0	0	4	0	27	0	0	0	27	0
Race												
White	48,375	152	4,085	12,127	31,907	104	408,958	1,411	42,475	83,402	281,082	588
African American	6,191	10	487	1,344	4,345	5	53,926	94	5,008	9,726	39,080	18
Other/unknown	62,725	519	3,172	13,762	45,243	29	543,102	5,208	33,183	98,115	406,436	160
Use of Nursing Facilities^c												
Entire year	67	12	55	0	0	0	657	133	524	0	0	0
Part year	100	11	83	3	3	0	998	107	824	31	36	0
None	117,124	658	7,606	27,230	81,492	138	1,004,331	6,473	79,318	191,212	726,562	766
Maintenance Assistance Status												
Cash	40,390	638	7,042	15,613	17,097	0	358,818	6,438	73,610	122,323	156,447	0
Medically needy	0	0	0	0	0	0		0	0	0	0	0
Poverty-related	67,341	0	1	9,379	57,823	138	562,942	0	8	52,452	509,716	766
Other/unknown	9,560	43	701	2,241	6,575	0	84,226	275	7,048	16,468	60,435	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	117,291	681	7,744	27,233	81,495	138	1,005,986	6,713	80,666	191,243	726,598	766
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0

0
0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c	Rx \$ as a Percentage of All Medicaid FFS \$ ^d	Number of Beneficiaries
All	54.0 %	6.7	\$519	\$77	\$5,665	9.2 %	117,291
Age							
5 and younger	51.9	2.2	155	70	4,364	3.6	31,207
6-14	43.9	2.9	266	92	3,299	8.1	37,466
15-20	53.3	4.5	429	95	6,827	6.3	19,432
21-44	67.2	11.4	837	73	7,269	11.5	22,274
45-64	77.6	39.3	2,849	73	15,243	18.7	6,139
65-74	81.1	35.6	2,091	59	19,042	11.0	471
75-84	84.0	39.0	2,005	51	24,546	8.2	243
85 and older	65.5	32.3	1,509	47	26,902	5.6	58
Unknown	0.0	0.0	0	0	11,779	0.0	1
Basis of Eligibility^e							
Aged	79.7	35.4	1,955	55	20,908	9.3	681
Disabled	82.4	45.4	4,061	90	27,219	14.9	7,744
Adults	64.3	7.2	469	65	4,869	9.6	27,233
Children	47.6	2.7	185	69	3,750	4.9	81,495
Unknown	61.6	11.5	1,716	150	9,128	18.8	138
Gender							
Female	57.8	7.8	532	68	5,737	9.3	64,621
Male	49.4	5.4	502	94	5,577	9.0	52,666
Unknown	50.0	0.8	11	15	362	3.1	4
Race							
White	58.2	8.7	705	81	5,525	12.8	48,375
African American	55.8	8.2	651	80	4,601	14.1	6,191
Other/unknown	50.6	5.0	362	72	5,877	6.2	62,725
Use of Nursing Facilities^f							
Entire year	98.5	87.8	7,007	80	124,981	5.6	67
Part year	98.0	94.0	7,757	83	113,723	6.8	100
None	54.0	6.6	509	77	5,504	9.2	117,124
Maintenance Assistance Status							
Cash	60.9	13.6	1,058	78	7,779	13.6	40,390
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	49.3	2.6	179	70	3,844	4.7	67,341
Other/unknown	58.0	7.2	628	87	9,559	6.6	9,560

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	Number of Rx, Percentage with:						Mean \$, All Medicaid FFS \$ ^d	Number	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10		Beneficiaries	Benefit Months
All	0.8	\$61	9.2 %	46.0 %	43.1 %	4.4 %	4.2 %	1.6 %	0.8 %	\$661	117,291	1,005,986
Age												
5 and younger	0.3	18	3.6	48.1	49.3	1.8	0.7	0.0	0.0	512	31,207	266,147
6-14	0.3	28	8.1	56.1	39.4	2.4	1.8	0.3	0.1	352	37,466	351,124
15-20	0.5	51	6.3	46.7	44.8	4.6	3.0	0.8	0.2	815	19,432	162,747
21-44	1.6	116	11.5	32.8	44.3	9.2	9.1	3.3	1.3	1,006	22,274	160,878
45-64	4.2	305	18.7	22.4	26.9	10.0	19.6	13.3	7.8	1,632	6,139	57,354
65-74	3.5	207	11.0	18.9	28.7	13.0	24.4	10.8	4.2	1,887	471	4,754
75-84	3.8	194	8.2	16.0	26.7	14.4	23.0	15.2	4.5	2,374	243	2,513
85 and older	4.0	187	5.6	34.5	19.0	3.4	27.6	12.1	3.4	3,341	58	467
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	5,890	1	2
Basis of Eligibility^e												
Aged	3.6	198	9.3	20.3	27.0	12.5	24.2	12.2	3.8	2,121	681	6,713
Disabled	4.4	390	14.9	17.6	28.1	10.7	20.6	13.9	9.1	2,613	7,744	80,666
Adults	1.0	67	9.6	35.7	46.1	8.4	7.4	2.0	0.4	693	27,233	191,243
Children	0.3	21	4.9	52.4	43.7	2.3	1.3	0.2	0.1	421	81,495	726,598
Unknown	2.1	309	18.8	38.4	26.8	14.5	15.9	4.3	0.0	1,645	138	766
Gender												
Female	0.9	63	9.3	42.2	44.9	5.1	4.8	2.0	0.9	683	64,621	542,531
Male	0.6	57	9.0	50.6	40.9	3.5	3.3	1.1	0.5	634	52,666	463,428
Unknown	0.1	2	3.1	50.0	50.0	0.0	0.0	0.0	0.0	54	4	27
Race												
White	1.0	83	12.8	41.8	43.7	5.5	5.5	2.4	1.1	654	48,375	408,958
African American	0.9	75	14.1	44.2	44.5	4.7	4.2	1.4	1.1	528	6,191	53,926
Other/unknown	0.6	42	6.2	49.4	42.6	3.4	3.1	1.0	0.5	679	62,725	543,102
Use of Nursing Facilities^f												
Entire year	9.0	715	5.6	1.5	6.0	3.0	31.3	35.8	22.4	12,745	67	657
Part year	9.4	777	6.8	2.0	8.0	9.0	23.0	27.0	31.0	11,395	100	998
None	0.8	59	9.2	46.0	43.2	4.3	4.1	1.6	0.7	642	117,124	1,004,331
Maintenance Assistance Status												
Cash	1.5	119	13.6	39.1	40.2	6.5	8.2	4.0	2.0	876	40,390	358,818
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.3	22	4.7	50.7	44.8	2.8	1.5	0.2	0.0	460	67,341	562,942
Other/unknown	0.8	71	6.6	42.0	43.6	6.2	6.0	1.6	0.7	1,085	9,560	84,226

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
All	0.8	\$61	\$77	0.3	\$46	\$137	0.1	\$5	\$74	0.4	\$10	\$26
Age												
5 and younger	0.3	18	70	0.1	14	155	0.0	1	46	0.1	3	20
6-14	0.3	28	92	0.2	24	147	0.0	1	69	0.1	3	25
15-20	0.5	51	95	0.2	42	171	0.0	3	69	0.3	6	25
21-44	1.6	116	73	0.6	83	137	0.1	10	82	0.8	22	26
45-64	4.2	305	73	1.8	220	121	0.3	28	84	2.0	56	28
65-74	3.5	207	59	1.6	154	94	0.3	15	57	1.6	38	24
75-84	3.8	194	51	1.7	146	85	0.3	11	35	1.7	38	22
85 and older	4.0	187	47	1.9	141	76	0.3	7	22	1.9	40	21
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility^d												
Aged	3.6	198	55	1.7	151	90	0.3	11	41	1.6	37	22
Disabled	4.4	390	90	2.0	302	151	0.4	31	84	2.0	57	29
Adults	1.0	67	65	0.3	46	136	0.1	6	82	0.6	15	24
Children	0.3	21	69	0.1	16	120	0.0	1	53	0.1	3	23
Unknown	2.1	309	150	0.9	267	282	0.1	17	146	1.0	26	26
Gender												
Female	0.9	63	68	0.4	46	120	0.1	5	71	0.5	12	25
Male	0.6	57	94	0.3	46	165	0.0	4	80	0.3	8	27
Unknown	0.1	2	15	0.0	0	0	0.0	0	0	0.1	2	15
Race												
White	1.0	83	81	0.5	64	137	0.1	6	92	0.5	14	28
African American	0.9	75	80	0.4	61	138	0.1	3	57	0.4	10	23
Other/unknown	0.6	42	72	0.2	31	138	0.1	4	61	0.3	7	24
Use of Nursing Facilities^e												
Entire year	9.0	715	80	3.5	503	145	1.3	80	60	4.1	129	31
Part year	9.4	777	83	3.7	561	152	0.9	59	66	4.8	157	33
None	0.8	59	77	0.3	45	137	0.1	5	75	0.4	10	26
Maintenance Assistance Status												
Cash	1.5	119	78	0.6	89	138	0.1	10	81	0.8	20	27
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Poverty related	0.3	22	70	0.1	17	130	0.0	1	55	0.2	3	22
Other/unknown	0.8	71	87	0.4	58	144	0.1	4	66	0.4	9	26

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called “innovator single-source drugs,” are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called “innovator multiple-source drugs,” are brand-name drugs whose patents have expired. Generic drugs, sometimes called “non-innovator multiple-source drugs,” are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 5.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users ^e				
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.1	0.0	0.1	\$15	\$9	\$2	\$4	\$63	\$121	\$81	\$28	84,531	\$5,361,257	37,627	32.1 %	368,810
Biologicals	0.5	0.5	0.0	0.0	568	568	0	0	1250	1,250	0	0	1,465	1,831,720	360	0.3	3,227
Antineoplastic Agents	0.6	0.2	0.1	0.4	158	127	11	20	264	816	203	52	2,532	668,853	415	0.4	4,231
Endocrine/Metabolic Drugs	0.6	0.2	0.1	0.2	30	19	5	6	55	91	43	26	60,891	3,331,714	11,721	10.0	110,435
Cardiovascular Agents	1.3	0.5	0.1	0.8	49	34	2	13	38	71	38	17	81,020	3,076,921	6,155	5.2	62,419
Respiratory Agents	0.4	0.2	0.0	0.2	26	22	0	4	64	93	102	22	74,471	4,761,732	18,619	15.9	185,337
Gastrointestinal Agents	0.5	0.3	0.0	0.2	60	50	3	6	109	152	90	34	41,334	4,492,494	7,587	6.5	75,253
Genitourinary Agents	0.3	0.2	0.0	0.1	15	11	2	2	54	71	47	27	9,257	496,285	3,422	2.9	32,158
CNS Drugs	1.2	0.7	0.1	0.5	116	97	5	14	94	141	83	30	153,477	14,489,331	12,740	10.9	124,875
Stimulants/Anti-obesity/Anorexia	0.7	0.5	0.0	0.1	69	62	2	5	100	113	73	46	24,892	2,501,227	3,486	3.0	36,224
Miscellaneous Psychological/																	
Neurological Agents	0.7	0.7	0.0	0.0	235	235	0	0	313	314	0	15	1,592	498,698	195	0.2	2,124
Analgesics and Anesthetics	0.5	0.1	0.0	0.3	32	20	4	9	65	170	114	25	106,819	6,890,898	22,849	19.5	215,685
Neuromuscular Agents	0.9	0.4	0.1	0.4	68	42	15	12	76	117	98	30	67,920	5,130,884	7,437	6.3	74,950
Nutritional Products	0.3	0.0	0.0	0.3	5	0	1	5	16	24	18	15	17,555	277,552	5,731	4.9	51,112
Hematological Agents	0.7	0.2	0.2	0.3	338	328	4	6	462	1,444	25	17	9,139	4,222,464	1,274	1.1	12,487
Topical Products	0.2	0.1	0.0	0.1	10	6	1	3	49	92	61	24	48,080	2,337,510	22,748	19.4	226,054
Miscellaneous Products	0.2	0.1	0.0	0.0	21	17	2	2	125	129	209	76	3,185	398,298	1,785	1.5	18,530
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	10	0	0	0	46	0	0	0	1,347	61,480	591	0.5	6,018
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	789,507	60,829,318	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispans.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 5.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispans.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Top 10 Drug Groups	Total Medicaid Rx \$	Users		Among Users			
		Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$9,088,357	5,123	4.4 %	54,531	1.0	\$171	\$167
ANTIDEPRESSANTS	4,408,193	11,563	9.9	115,505	0.6	60	38
ANTICONVULSANT	4,369,828	4,774	4.1	50,240	0.9	98	87
ANALGESICS - Narcotic	4,157,219	23,457	20.0	226,140	0.3	60	18
MISC. HEMATOLOGICAL	3,444,397	265	0.2	2,848	0.8	1,456	1,209
ANTIASTHMATIC	3,004,324	16,056	13.7	163,121	0.3	71	18
ULCER DRUGS	2,975,586	6,715	5.7	67,870	0.5	96	44
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	2,501,227	4,110	3.5	43,084	0.6	100	58
ANALGESICS - ANTI-INFLAMMATORY	2,003,915	13,289	11.3	128,385	0.2	66	16
PASSIVE IMMUNIZING AGENTS	1,830,396	326	0.3	2,852	0.5	1,275	642
Total	37,783,442	85,678		854,576	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	All Top 10 Drug Groups		ANTIPSYCHOTICS					ANTIDEPRESSANTS				
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Months Among Users	Number of Rx per Month	Mean Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Months Among Users	Number of Rx per Month	Mean Rx \$ per Month
All	373,220	\$37,783,442	5,123	4.4 %	54,531	1.0	\$167	11,563	9.9 %	115,505	0.6	\$38
Female	230,251	19,455,053	2,657	4.1	28,035	1.0	147	8,344	12.9	82,192	0.6	38
Disabled	110,979	10,578,821	1,257	31.9	14,144	1.4	207	2,480	62.9	27,466	1.0	54
5 and younger	578	185,191	2	1.1	17	1.0	158	2	1.1	14	0.4	5
6-14	2,350	330,005	53	19.6	610	0.9	189	46	17.0	523	0.6	27
15-20	2,891	370,304	71	28.4	805	0.9	158	77	30.8	862	0.7	47
21-44	40,111	3,717,981	544	41.4	6,044	1.3	203	912	69.4	10,088	1.0	54
45-64	63,839	5,867,920	576	30.9	6,536	1.5	221	1,414	75.9	15,648	1.0	54
65-74	1,210	107,420	11	15.7	132	0.5	62	29	41.4	331	0.8	53
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	119,272	8,876,232	1,400	2.3	13,891	0.6	85	5,864	9.7	54,726	0.4	31
5 and younger	5,347	806,961	12	0.1	125	0.3	41	17	0.1	185	0.3	18
6-14	17,082	1,377,985	300	1.7	3,186	0.7	105	481	2.7	5,143	0.5	28
15-20	21,651	1,445,995	456	4.5	4,598	0.6	89	1,251	12.3	12,190	0.5	30
21-44	58,577	3,888,278	511	3.3	4,728	0.4	63	3,451	22.1	30,815	0.4	31
45-64	12,240	1,005,620	87	5.4	876	0.7	103	600	37.2	5,722	0.5	33
65-74	2,411	206,367	19	8.1	211	1.4	135	33	14.0	356	0.7	34
75-84	1,642	118,971	10	6.2	113	1.0	117	25	15.4	263	1.2	51
85 and older	322	26,055	5	12.2	54	1.6	140	6	14.6	52	1.6	68
Male	142,969	18,328,389	2,466	4.7	26,496	1.0	188	3,219	6.1	33,313	0.7	38
Disabled	68,575	10,247,858	1,226	32.3	13,684	1.3	245	1,298	34.2	14,309	0.9	46
5 and younger	964	304,945	3	1.3	35	0.6	223	3	1.3	34	0.1	12
6-14	6,392	2,042,619	193	34.8	2,203	0.9	189	107	19.3	1,209	0.6	39
15-20	5,175	1,880,350	147	34.4	1,626	1.0	188	97	22.7	1,069	0.8	44
21-44	23,753	2,900,188	551	51.0	6,117	1.5	286	429	39.7	4,667	1.0	54
45-64	31,534	3,067,244	327	22.1	3,643	1.4	237	651	44.0	7,202	0.9	43
65-74	757	52,512	5	16.7	60	3.0	228	11	36.7	128	0.9	36
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	74,394	8,080,531	1,240	2.5	12,812	0.7	127	1,921	3.9	19,004	0.5	32
5 and younger	8,562	1,458,839	25	0.2	266	0.6	128	15	0.1	155	0.2	9
6-14	31,404	3,110,517	653	3.5	7,031	0.6	131	642	3.5	6,823	0.5	30
15-20	17,193	2,132,024	445	5.2	4,485	0.7	128	644	7.5	6,349	0.6	36
21-44	10,480	853,420	81	1.9	722	0.3	79	431	10.0	3,823	0.4	28
45-64	4,605	353,573	21	1.8	173	0.4	58	159	13.4	1,536	0.4	28
65-74	1,205	102,321	7	5.1	63	1.0	281	15	11.0	156	0.7	26
75-84	742	61,258	4	5.0	42	1.1	139	11	13.8	127	0.9	52
85 and older	203	8,579	4	23.5	30	1.8	80	4	23.5	35	2.7	65
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	ANTICONVULSANT					ANALGESICS - Narcotic					MISC. HEMATOLOGICAL				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean	Mean Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean	Mean Rx \$ per Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean	Mean Rx \$ per Month
				Number of Rx per Benefit Month					Number of Rx per Benefit Month					Number of Rx per Benefit Month	
All	4,774	4.1 %	50,240	0.9	\$87	23,457	20.0 %	226,140	0.3	\$18	265	0.2 %	2,848	0.8	\$1,209
Female	2,930	4.5	30,597	0.9	84	16,181	25.0	154,314	0.3	18	153	0.2	1,668	0.9	106
Disabled	1,380	35.0	15,378	1.2	110	3,001	76.1	33,616	0.5	42	110	2.8	1,222	1.0	119
5 and younger	23	12.9	251	0.6	109	15	8.4	177	0.1	1	0	0.0	0	0.0	0
6-14	85	31.5	959	0.8	144	28	10.4	320	0.1	1	0	0.0	0	0.0	0
15-20	85	34.0	983	0.8	143	55	22.0	610	0.1	2	0	0.0	0	0.0	0
21-44	544	41.4	6,046	1.3	116	1,118	85.1	12,517	0.5	41	23	1.8	268	1.1	103
45-64	632	33.9	7,007	1.1	97	1,749	93.9	19,568	0.5	46	84	4.5	918	0.9	124
65-74	11	15.7	132	1.0	90	36	51.4	424	0.3	12	3	4.3	36	0.7	94
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	1,550	2.6	15,219	0.5	57	13,180	21.7	120,698	0.3	11	43	0.1	446	0.6	70
5 and younger	43	0.3	419	0.4	33	388	2.6	3,927	0.1	2	0	0.0	0	0.0	0
6-14	215	1.2	2,259	0.7	66	1,172	6.5	12,276	0.1	2	0	0.0	0	0.0	0
15-20	295	2.9	2,932	0.6	62	2,565	25.3	23,898	0.2	2	1	0.0	12	0.1	2
21-44	806	5.2	7,656	0.5	52	7,996	51.3	70,110	0.3	14	14	0.1	134	0.4	47
45-64	175	10.9	1,782	0.5	66	899	55.8	8,728	0.4	26	9	0.6	89	0.6	84
65-74	14	6.0	147	0.9	55	85	36.2	921	0.3	18	9	3.8	93	0.5	101
75-84	2	1.2	24	0.2	3	68	42.0	771	0.3	14	7	4.3	82	0.7	59
85 and older	0	0.0	0	0.0	0	7	17.1	67	0.1	2	3	7.3	36	0.9	87
Male	1,844	3.5	19,643	0.9	92	7,276	13.8	71,826	0.3	20	112	0.2	1,180	0.8	2,770
Disabled	990	26.1	10,978	1.1	113	1,710	45.0	18,494	0.5	47	81	2.1	868	0.7	2,789
5 and younger	32	14.2	352	0.8	119	19	8.4	213	0.2	2	0	0.0	0	0.0	0
6-14	153	27.6	1,730	0.8	118	59	10.6	679	0.1	3	3	0.5	34	0.8	33,198
15-20	95	22.2	1,066	1.1	135	88	20.6	960	0.2	15	2	0.5	18	0.9	68,525
21-44	363	33.6	4,039	1.2	122	509	47.1	5,464	0.4	28	3	0.3	35	0.3	37
45-64	341	23.0	3,719	1.2	95	1,022	69.0	11,024	0.6	63	72	4.9	769	0.7	74
65-74	6	20.0	72	1.1	31	13	43.3	154	0.4	63	1	3.3	12	0.1	11
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	854	1.7	8,665	0.7	66	5,566	11.4	53,332	0.2	10	31	0.1	312	1.0	2,717
5 and younger	50	0.3	511	0.6	84	622	3.9	6,390	0.1	1	3	0.0	29	0.2	1,128
6-14	351	1.9	3,768	0.7	62	1,247	6.7	13,086	0.1	2	1	0.0	12	1.0	9,857
15-20	207	2.4	2,098	0.9	81	1,494	17.3	14,265	0.1	2	2	0.0	18	0.5	34,522
21-44	160	3.7	1,423	0.5	58	1,679	39.1	14,558	0.3	22	5	0.1	52	0.5	1,115
45-64	63	5.3	624	0.6	48	449	37.9	4,214	0.4	29	7	0.6	74	0.7	56
65-74	12	8.8	112	1.5	61	47	34.6	500	0.3	46	7	5.1	65	2.4	130
75-84	9	11.3	107	0.8	33	27	33.7	307	0.2	5	5	6.3	60	0.6	77
85 and older	2	11.8	22	0.2	6	1	5.9	12	0.8	9	1	5.9	2	0.5	68
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	ANTIASTHMATIC					ULCER DRUGS					STIMULANTS/ANTI-OBESITY/ANOREXIANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	16,056	13.7 %	163,121	0.3	\$18	6,715	5.7 %	67,870	0.5	\$44	4,110	3.5 %	43,084	0.6	\$58
Female	9,041	14.0	91,228	0.3	19	4,642	7.2	46,603	0.5	43	1,257	1.9	13,175	0.5	59
Disabled	1,789	45.3	19,905	0.4	31	1,574	39.9	17,448	0.7	65	209	5.3	2,363	0.6	68
5 and younger	63	35.4	693	0.2	18	32	18.0	318	0.3	20	3	1.7	28	0.1	4
6-14	60	22.2	694	0.3	21	28	10.4	327	0.4	40	44	16.3	505	0.7	64
15-20	50	20.0	588	0.3	22	30	12.0	342	0.4	47	37	14.8	422	0.6	56
21-44	509	38.7	5,720	0.3	26	448	34.1	4,946	0.7	61	53	4.0	585	0.6	75
45-64	1,075	57.7	11,842	0.5	37	988	53.1	10,960	0.7	70	71	3.8	811	0.5	75
65-74	32	45.7	368	0.3	19	48	68.6	555	0.6	49	1	1.4	12	0.8	26
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	7,252	12.0	71,323	0.2	15	3,068	5.1	29,155	0.3	30	1,048	1.7	10,812	0.5	57
5 and younger	1,715	11.5	17,249	0.2	9	224	1.5	2,040	0.2	18	25	0.2	239	0.2	26
6-14	1,872	10.4	19,482	0.2	15	330	1.8	3,499	0.2	18	586	3.2	6,241	0.6	54
15-20	1,119	11.0	10,915	0.2	16	459	4.5	4,392	0.2	20	218	2.2	2,211	0.5	52
21-44	2,029	13.0	18,413	0.2	16	1,529	9.8	13,946	0.3	31	185	1.2	1,777	0.6	75
45-64	387	24.0	3,796	0.3	23	358	22.2	3,420	0.4	42	34	2.1	344	0.5	61
65-74	86	36.6	940	0.4	31	101	43.0	1,108	0.6	56	0	0.0	0	0.0	0
75-84	42	25.9	504	0.4	38	56	34.6	630	0.7	65	0	0.0	0	0.0	0
85 and older	2	4.9	24	0.5	43	11	26.8	120	0.7	84	0	0.0	0	0.0	0
Male	7,015	13.3	71,893	0.2	18	2,073	3.9	21,267	0.5	45	2,853	5.4	29,909	0.6	58
Disabled	900	23.7	9,978	0.4	35	869	22.9	9,543	0.7	63	343	9.0	3,842	0.6	66
5 and younger	83	36.9	942	0.3	25	30	13.3	328	0.3	43	14	6.2	158	0.3	22
6-14	119	21.4	1,348	0.3	49	43	7.7	493	0.5	63	195	35.1	2,191	0.7	67
15-20	77	18.0	893	0.3	25	51	11.9	560	0.5	53	76	17.8	866	0.7	74
21-44	160	14.8	1,790	0.4	22	233	21.6	2,591	0.6	55	30	2.8	343	0.5	68
45-64	455	30.7	4,933	0.5	40	497	33.6	5,391	0.8	68	28	1.9	284	0.5	56
65-74	6	20.0	72	0.4	45	15	50.0	180	1.2	80	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	6,115	12.5	61,915	0.2	16	1,204	2.5	11,724	0.3	31	2,510	5.1	26,067	0.6	57
5 and younger	2,595	16.3	25,989	0.2	12	269	1.7	2,512	0.2	19	118	0.7	1,298	0.3	34
6-14	2,284	12.3	23,969	0.2	17	235	1.3	2,473	0.2	24	1,849	9.9	19,356	0.6	58
15-20	725	8.4	7,222	0.2	19	171	2.0	1,679	0.3	24	504	5.8	5,064	0.5	55
21-44	303	7.1	2,655	0.3	16	292	6.8	2,646	0.3	40	38	0.9	337	0.4	62
45-64	124	10.5	1,195	0.3	24	173	14.6	1,705	0.4	45	1	0.1	12	0.3	57
65-74	38	27.9	387	0.4	33	39	28.7	420	0.6	54	0	0.0	0	0.0	0
75-84	39	48.8	438	0.5	53	23	28.8	270	0.3	42	0	0.0	0	0.0	0
85 and older	7	41.2	60	0.3	23	2	11.8	19	0.5	87	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY					PASSIVE IMMUNIZING AGENTS					Number of Beneficiaries	Number of Benefit Months
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month		
All	13,289	11.3 %	128,385	0.2	\$16	326	0.3 %	2,852	0.5	\$642	117,291	1,005,986
Female	9,407	14.6	90,018	0.2	17	134	0.2	1,162	0.5	603	64,620	542,529
Disabled	1,633	41.4	18,468	0.4	46	23	0.6	214	0.5	634	3,945	41,660
5 and younger	5	2.8	50	0.1	2	23	12.9	214	0.5	634	178	1,616
6-14	11	4.1	127	0.2	26	0	0.0	0	0.0	0	270	2,903
15-20	37	14.8	432	0.2	20	0	0.0	0	0.0	0	250	2,680
21-44	560	42.6	6,365	0.4	32	0	0.0	0	0.0	0	1,314	14,022
45-64	988	53.1	11,110	0.5	55	0	0.0	0	0.0	0	1,862	19,643
65-74	32	45.7	384	0.3	69	0	0.0	0	0.0	0	70	793
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	3
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	7,774	12.8	71,550	0.2	9	111	0.2	948	0.5	596	60,675	500,869
5 and younger	405	2.7	3,936	0.1	3	102	0.7	880	0.5	640	14,855	126,531
6-14	683	3.8	7,033	0.1	4	0	0.0	0	0.0	0	18,052	167,855
15-20	1,611	15.9	15,039	0.2	4	4	0.0	28	0.1	19	10,134	83,002
21-44	4,302	27.6	37,844	0.2	10	5	0.0	40	0.2	18	15,585	105,807
45-64	644	40.0	6,240	0.3	20	0	0.0	0	0.0	0	1,611	13,254
65-74	74	31.5	838	0.5	49	0	0.0	0	0.0	0	235	2,398
75-84	49	30.2	548	0.6	30	0	0.0	0	0.0	0	162	1,695
85 and older	6	14.6	72	0.3	8	0	0.0	0	0.0	0	41	327
Male	3,882	7.4	38,367	0.2	12	192	0.4	1,690	0.5	669	52,666	463,428
Disabled	829	21.8	9,211	0.3	31	31	0.8	323	0.6	660	3,799	39,006
5 and younger	11	4.9	111	0.1	2	31	13.8	323	0.6	660	225	2,055
6-14	13	2.3	149	0.2	3	0	0.0	0	0.0	0	555	6,061
15-20	45	10.5	494	0.2	42	0	0.0	0	0.0	0	427	4,494
21-44	245	22.7	2,726	0.3	19	0	0.0	0	0.0	0	1,081	11,152
45-64	500	33.8	5,551	0.4	38	0	0.0	0	0.0	0	1,481	14,907
65-74	15	50.0	180	0.4	26	0	0.0	0	0.0	0	30	337
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	3,053	6.2	29,156	0.2	7	161	0.3	1,367	0.5	671	48,867	424,422
5 and younger	465	2.9	4,483	0.1	2	161	1.0	1,367	0.5	671	15,945	135,918
6-14	584	3.1	5,949	0.1	2	0	0.0	0	0.0	0	18,589	174,305
15-20	868	10.1	8,345	0.1	6	0	0.0	0	0.0	0	8,621	72,571
21-44	810	18.9	7,154	0.2	9	0	0.0	0	0.0	0	4,294	29,897
45-64	268	22.6	2,569	0.2	15	0	0.0	0	0.0	0	1,185	9,550
65-74	29	21.3	331	0.4	22	0	0.0	0	0.0	0	136	1,226
75-84	25	31.3	282	0.3	17	0	0.0	0	0.0	0	80	815
85 and older	4	23.5	43	0.2	12	0	0.0	0	0.0	0	17	140
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	5	29

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	\$715	9.0	67	657
Age				
0-64	813	10.0	54	512
65-74	273	4.9	5	60
75-84	586	6.6	4	48
85 and older	233	4.2	4	37
Unknown	0	0.0	0	0
Gender				
Female	674	9.4	42	398
Male	778	8.3	25	259
Unknown	0	0.0	0	0
Race				
White	783	11.8	31	275
African American	270	3.9	4	38
Other/unknown	709	7.2	32	344
Basis of Eligibility^c				
Aged	387	5.4	12	133
Disabled	798	9.9	55	524
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Total Number of Rx	Total Rx \$	Users		
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic			Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.4	0.2	0.0	0.2	\$66	\$56	\$3	\$7	\$160	\$261	\$102	\$42	177	\$28,232	39	58.2 %	427
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	1.0	0.4	0.0	0.6	84	26	0	58	86	69	0	98	38	3,285	5	7.5	39
Endocrine/Metabolic Drugs	1.9	0.7	0.2	0.9	64	41	5	18	34	57	24	19	432	14,692	25	37.3	229
Cardiovascular Agents	2.4	1.0	0.1	1.3	87	61	3	24	37	61	32	19	661	24,561	29	43.3	281
Respiratory Agents	1.0	0.6	0.1	0.2	82	71	6	5	86	112	90	20	192	16,557	22	32.8	201
Gastrointestinal Agents	1.6	0.7	0.3	0.7	117	88	10	18	71	124	38	28	789	56,194	50	74.6	482
Genitourinary Agents	0.5	0.3	0.1	0.1	45	35	4	7	87	111	32	77	82	7,141	16	23.9	157
CNS Drugs	2.4	1.2	0.3	0.9	232	180	23	28	95	145	88	31	1,288	122,536	52	77.6	529
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/ Neurological Agents	0.8	0.0	0.0	0.8	19	2	0	17	22	90	0	21	39	874	4	6.0	46
Neurological Agents	1.1	1.1	0.0	0.0	576	576	0	0	540	540	0	0	65	35,110	6	9.0	61
Analgesics and Anesthetics	1.8	0.8	0.2	0.8	178	135	25	18	99	168	123	23	688	68,317	41	61.2	383
Neuromuscular Agents	1.8	0.2	0.6	1.0	123	30	38	55	70	149	67	55	867	60,594	47	70.1	493
Nutritional Products	1.3	0.0	0.1	1.2	21	0	4	17	17	0	47	14	135	2,228	11	16.4	107
Hematological Agents	1.7	0.3	0.9	0.5	193	170	7	15	111	607	8	29	173	19,285	11	16.4	100
Topical Products	0.6	0.1	0.1	0.4	21	7	2	12	36	65	45	28	235	8,509	38	56.7	397
Miscellaneous Products	0.1	0.0	0.0	0.1	3	0	0	3	31	0	0	31	2	61	2	3.0	23
Unknown Therapeutic Category	0.4	0.0	0.0	0.0	22	0	0	0	62	0	0	0	21	1,294	6	9.0	59
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,884	469,470	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. Brand-name drugs, sometimes called “innovator single-source drugs,” are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called “innovator multiple-source drugs,” are brand-name drugs whose patents have expired. Generic drugs, sometimes called “non-innovator multiple-source drugs,” are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Alaska, 5.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users			Among Users		
		Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$66,742	28	41.8 %	283	1.0	\$225	\$236
ANTIDEPRESSANTS	50,086	50	74.6	528	1.4	69	95
ANTICONVULSANT	42,412	43	64.2	464	1.2	74	91
ULCER DRUGS	40,405	35	52.2	359	1.2	94	113
ANALGESICS - Narcotic	34,368	43	64.2	407	1.0	82	84
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	35,110	7	10.4	73	0.9	540	481
ANALGESICS - ANTI-INFLAMMATORY	27,799	15	22.4	174	1.2	134	160
MUSCULOSKELETAL THERAPY AGENTS	16,702	17	25.4	177	1.4	65	94
ANTIVIRAL	16,244	4	6.0	48	0.7	464	338
HEMATOPOIETIC AGENTS	12,113	6	9.0	52	0.8	275	233
Total	341,981	248		2,565	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST
 AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	All Top 10 Drug Groups		ANTIPSYCHOTICS					ANTIDEPRESSANTS				
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	3,046	\$341,981	28	41.8 %	283	1.0	\$236	50	74.6 %	528	1.4	\$95
Female	1,831	195,383	10	23.8	120	1.1	227	29	69.0	302	1.5	110
Disabled	1,636	175,912	6	17.6	72	1.1	249	29	85.3	302	1.5	110
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	195	19,471	4	50.0	48	1.1	194	0	0.0	0	0.0	0
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	145	11,321	3	75.0	36	1.2	152	0	0.0	0	0.0	0
75-84	25	5,650	1	100.0	12	1.0	320	0	0.0	0	0.0	0
85 and older	25	2,500	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male	1,215	146,598	18	72.0	163	1.0	242	21	84.0	226	1.3	74
Disabled	1,056	131,743	16	76.2	139	1.0	248	17	81.0	180	1.3	69
64 or younger	1,039	130,679	16	80.0	139	1.0	248	16	80.0	168	1.4	68
65-74	17	1,064	0	0.0	0	0.0	0	1	100.0	12	0.9	80
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	159	14,855	2	50.0	24	1.2	209	4	100.0	46	1.0	95
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	140	12,900	2	66.7	24	1.2	209	3	100.0	36	1.0	100
75-84	19	1,955	0	0.0	0	0.0	0	1	100.0	10	0.9	75
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	ANTICONVULSANT					ULCER DRUGS					ANALGESICS - Narcotic				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	43	64.2 %	464	1.2	\$91	35	52.2 %	359	1.2	\$113	43	64.2 %	407	1.0	\$84
Female	20	47.6	223	1.4	119	21	50.0	211	1.2	110	31	73.8	289	1.0	90
Disabled	17	50.0	187	1.5	136	14	41.2	127	1.4	117	27	79.4	241	1.1	106
64 or younger	17	50.0	187	1.5	136	14	41.2	127	1.4	117	27	79.4	241	1.1	106
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	3	37.5	36	0.9	30	7	87.5	84	0.9	100	4	50.0	48	0.6	5
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	3	75.0	36	0.9	30	4	100.0	48	0.9	94	3	75.0	36	0.7	7
75-84	0	0.0	0	0.0	0	1	100.0	12	1.1	150	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	2	66.7	24	0.9	86	1	33.3	12	0.1	1
Male	23	92.0	241	1.1	66	14	56.0	148	1.2	116	12	48.0	118	1.0	72
Disabled	19	90.5	195	1.1	74	13	61.9	136	1.2	115	9	42.9	82	1.4	103
64 or younger	19	95.0	195	1.1	74	13	65.0	136	1.2	115	8	40.0	70	1.6	120
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	100.0	12	0.5	9
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	4	100.0	46	1.2	33	1	25.0	12	0.9	128	3	75.0	36	0.1	1
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	3	100.0	36	1.4	39	1	33.3	12	0.9	128	3	100.0	36	0.1	1
85 and older	1	100.0	10	0.3	11	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					ANALGESICS - ANTI-INFLAMMATORY					MUSCULOSKELETAL THERAPY AGENTS				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	7	10.4 %	73	0.9	\$481	15	22.4 %	174	1.2	\$160	17	25.4 %	177	1.4	\$94
Female	5	11.9	51	0.9	426	9	21.4	105	1.2	231	13	31.0	134	1.5	98
Disabled	4	11.8	48	0.9	443	9	26.5	105	1.2	231	13	38.2	134	1.5	98
64 or younger	4	11.8	48	0.9	443	9	26.5	105	1.2	231	13	38.2	134	1.5	98
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	1	12.5	3	1.0	144	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	1	33.3	3	1.0	144	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male	2	8.0	22	0.8	609	6	24.0	69	1.1	52	4	16.0	43	1.1	82
Disabled	1	4.8	12	0.9	1,026	5	23.8	57	1.2	46	4	19.0	43	1.1	82
64 or younger	1	5.0	12	0.9	1,026	5	25.0	57	1.2	46	4	20.0	43	1.1	82
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	1	25.0	10	0.7	110	1	25.0	12	0.8	83	0	0.0	0	0.0	0
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	1	33.3	12	0.8	83	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	1	100.0	10	0.7	110	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	ANTIVIRAL					HEMATOPOIETIC AGENTS					Benefit Months	
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Among All-Year Nursing Facility Residents
All	4	6.0 %	48	0.7	\$338	6	9.0 %	52	0.8	\$233	67	657
Female	0	0.0	0	0.0	0	2	4.8	13	1.0	14	42	398
Disabled	0	0.0	0	0.0	0	2	5.9	13	1.0	14	34	311
64 or younger	0	0.0	0	0.0	0	2	5.9	13	1.0	14	34	311
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	8	87
Other Eligibles	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	48
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	27
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male	4	16.0	48	0.7	338	4	16.0	39	0.8	306	25	259
Disabled	3	14.3	36	0.9	442	4	19.0	39	0.8	306	21	213
64 or younger	3	15.0	36	0.9	442	4	20.0	39	0.8	306	20	201
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	1	25.0	12	0.2	27	0	0.0	0	0.0	0	4	46
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	1	33.3	12	0.2	27	0	0.0	0	0.0	0	3	36
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	10
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 100 beneficiaries who were in nursing facilities for part of their enrollment and their 998 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2004

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	Part D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx \$ as a Percentage of All Nondual Rx \$	Total Number of Beneficiaries
All	10,428	8.9 %	0.4	43,281	\$8	\$889,342	\$21	1.5 %	117,291
Age									
5 and younger	1,735	5.6	0.1	3,401	2	67,824	20	1.4	31,207
6-14	1,024	2.7	0.1	2,481	2	79,921	32	0.8	37,466
15-20	1,377	7.1	0.2	3,250	4	78,302	24	0.9	19,432
21-44	4,315	19.4	0.8	18,312	15	342,233	19	1.8	22,274
45-64	1,807	29.4	2.3	14,229	48	295,826	21	1.7	6,139
65-74	105	22.3	2.2	1,037	36	17,041	16	1.7	471
75-84	55	22.6	2.1	501	29	7,133	14	1.5	243
85 and older	10	17.2	1.2	70	18	1,062	15	1.2	58
Unknown	0	0.0	0.0	0	0	0	0	0.0	1
Basis of Eligibility^c									
Aged	144	21.1	2.0	1,377	30	20,183	15	1.5	681
Disabled	2,475	32.0	2.8	21,382	68	527,741	25	1.7	7,744
Adults	4,478	16.4	0.5	14,112	8	227,628	16	1.8	27,233
Children	3,303	4.1	0.1	6,305	1	110,668	18	0.7	81,495
Unknown	28	20.3	0.8	105	23	3,122	30	1.3	138
Gender									
Female	7,456	11.5	0.5	31,140	9	608,919	20	1.8	64,621
Male	2,971	5.6	0.2	12,140	5	280,418	23	1.1	52,666
Unknown	1	25.0	0.3	1	1	5	5	11.1	4
Race									
White	4,623	9.6	0.5	24,200	11	546,777	23	1.6	48,375
African American	366	5.9	0.3	1,671	6	34,318	21	0.9	6,191
Other/unknown	5,439	8.7	0.3	17,410	5	308,247	18	1.4	62,725
Use of Nursing Facilities^d									
Entire year	35	52.2	6.1	410	109	7,319	18	1.6	67
Part year	74	74.0	7.6	764	168	16,750	22	2.2	100
None	10,319	8.8	0.4	42,107	7	865,273	21	1.5	117,124
Maintenance Assistance Status									
Cash	5,730	14.2	0.8	32,411	17	692,305	21	1.6	40,390
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	3,867	5.7	0.1	7,606	2	112,152	15	0.9	67,341
Other/unknown	831	8.7	0.3	3,264	9	84,885	26	1.4	9,560

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2004

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.0	\$1	\$21	\$0	\$0	1,005,986
Age						
5 and younger	0.0	0	20	0	0	266,147
6-14	0.0	0	32	0	0	351,124
15-20	0.0	0	24	0	0	162,747
21-44	0.1	2	19	0	1	160,878
45-64	0.2	5	21	0	3	57,354
65-74	0.2	4	16	0	1	4,754
75-84	0.2	3	14	0	1	2,513
85 and older	0.1	2	15	0	0	467
Unknown	0.0	0	0	0	0	2
Basis of Eligibility^c						
Aged	0.2	3	15	0	1	6,713
Disabled	0.3	7	25	0	4	80,666
Adults	0.1	1	16	0	1	191,243
Children	0.0	0	18	0	0	726,598
Unknown	0.1	4	30	0	2	766
Gender						
Female	0.1	1	20	0	1	542,531
Male	0.0	1	23	0	0	463,428
Unknown	0.0	0	5	0	0	27
Race						
White	0.1	1	23	0	1	408,958
African American	0.0	1	21	0	0	53,926
Other/unknown	0.0	1	18	0	0	543,102
Use of Nursing Facilities^d						
Entire year	0.6	11	18	0	7	657
Part year	0.8	17	22	0	8	998
None	0.0	1	21	0	0	1,004,331
Maintenance Assistance Status						
Cash	0.1	2	21	0	1	358,818
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	15	0	0	562,942
Other/unknown	0.0	1	26	0	0	84,226

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 ALASKA, 2004

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a	Total Number Rx.	\$ per Rx	Number Rx as a
				Percentage of All Part D Excluded Rx \$			Percentage of All Part D Excluded Rx
All	11,946	\$74	\$889,342	100.0 %	43,281	\$21	100.0 %
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	3	187	561	0.1	3	187	0.0
Drugs for cosmetic purposes	42	23	968	0.1	55	18	0.1
Cough and cold medications	702	97	67,886	7.6	1,318	52	3.0
Vitamins and minerals	2,026	77	156,338	17.6	8,264	19	19.1
Non-prescription drugs	3,880	27	106,674	12.0	10,069	11	23.3
Barbiturates	143	79	11,234	1.3	905	12	2.1
Benzodiazepines	4,029	121	486,372	54.7	20,104	24	46.4
Other Part D Excl Rx Drugs	1,121	53	59,309	6.7	2,563	23	5.9

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1
 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2004

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	117,291	681	7,744	27,233	81,495	138	1,005,986	6,713	80,666	191,243	726,598	766
Age												
5 and younger	31,207	0	403	0	30,804	0	266,147	0	3,671	0	262,476	0
6-14	37,466	0	825	7	36,634	0	351,124	0	8,964	48	342,112	0
15-20	19,432	0	677	4,894	13,854	7	162,747	0	7,174	34,382	121,164	27
21-44	22,274	1	2,395	19,589	203	86	160,878	9	25,174	134,482	846	367
45-64	6,139	11	3,343	2,740	0	45	57,354	115	34,550	22,317	0	372
65-74	471	369	100	2	0	0	4,754	3,612	1,130	12	0	0
75-84	243	242	1	0	0	0	2,513	2,510	3	0	0	0
85 and older	58	58	0	0	0	0	467	467	0	0	0	0
Unknown	1	0	0	1	0	0		0	0	2	0	0
Gender												
Female	64,621	445	3,945	20,277	39,816	138	542,531	4,496	41,660	140,260	355,349	766
Male	52,666	236	3,799	6,956	41,675	0	463,428	2,217	39,006	50,983	371,222	0
Unknown	4	0	0	0	4	0	27	0	0	0	27	0
Race												
White	48,375	152	4,085	12,127	31,907	104	408,958	1,411	42,475	83,402	281,082	588
African American	6,191	10	487	1,344	4,345	5	53,926	94	5,008	9,726	39,080	18
Other/unknown	62,725	519	3,172	13,762	45,243	29	543,102	5,208	33,183	98,115	406,436	160
Use of Nursing Facilities^c												
Entire year	67	12	55	0	0	0	657	133	524	0	0	0
Part year	100	11	83	3	3	0	998	107	824	31	36	0
None	117,124	658	7,606	27,230	81,492	138	1,004,331	6,473	79,318	191,212	726,562	766
Maintenance Assistance Status												
Cash	40,390	638	7,042	15,613	17,097	0	358,818	6,438	73,610	122,323	156,447	0
Medically needy	0	0	0	0	0	0		0	0	0	0	0
Poverty related	67,341	0	1	9,379	57,823	138	562,942	0	8	52,452	509,716	766
Other/unknown	9,560	43	701	2,241	6,575	0	84,226	275	7,048	16,468	60,435	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	117,291	681	7,744	27,233	81,495	138	1,005,986	6,713	80,666	191,243	726,598	766
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0
							0					
							0					
							0					
							0					

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, ALASKA, 2004

	Beneficiaries and Benefit Months in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	117,291	1,005,986	117,291	1,005,986	0	0
Fee-for-service (FFS) all year	117,291	1,005,986	117,291	1,005,986	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2004 file for Alaska, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.